文献速递冠心病

心肌梗死期间静脉给予他汀与梗死后口服给药的比较

Intravenous Statin Administration During Myocardial Infarction Compared With Oral Post-Infarct Administration.
PubMed 文献 · J Am Coll Cardiol · 2020-01-01

该研究在高胆固醇猪心肌梗死模型中比较了梗死期间静脉注射阿托伐他汀与梗死后2小时内口服阿托伐他汀的心脏保护作用。结果显示,静脉给药组在梗死面积、心肌挽救、瘢痕大小及心功能方面均优于口服组,提示该给药方式值得在ST段抬高型心肌梗死患者中进一步研究。

要点

  • 梗死期间静脉给予阿托伐他汀较梗死后口服进一步缩小梗死面积并增加心肌挽救。
  • 静脉给药组第42天瘢痕面积较口服组进一步减少24%,心功能改善更明显。
  • 该给药策略值得在ST段抬高型心肌梗死患者中开展临床研究。

核心结论

  • 心肌梗死期间静脉给予阿托伐他汀比再灌注后不久口服给药更大程度地限制心脏损伤、改善心功能并减轻重构。

研究设计与样本

  • 高胆固醇猪接受90分钟缺血诱导心肌梗死并观察42天,分为梗死期间静脉阿托伐他汀组、静脉溶媒组和梗死后2小时内口服阿托伐他汀组。
  • 静脉阿托伐他汀组和口服阿托伐他汀组随后42天维持每日口服阿托伐他汀。
  • 研究进行心脏磁共振分析(梗死后第3天和第42天)及分子和组织学研究。

主要发现

  • 第3天,静脉阿托伐他汀组梗死面积较口服组和溶媒组减少10%,心肌挽救增加50%。
  • 第42天,静脉组和口服组瘢痕面积均较溶媒组显著减小,但静脉组较口服组进一步减少24%。
  • 第42天,静脉组收缩功能较溶媒组改善,危险心肌节段室壁运动异常较口服组和溶媒组均减少。
  • 静脉组瘢痕内胶原含量和AMP活化蛋白激酶激活增强,半暗带血管密度增加,血浆肿瘤坏死因子α水平升高,外周血单核细胞活化降低。

临床怎么用

  • 在ST段抬高型心肌梗死患者中,可考虑进一步研究梗死期间静脉给予他汀的时机与方案。

局限性

  • 研究为高胆固醇猪心肌梗死模型,样本量未报告,结果需在ST段抬高型心肌梗死患者中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Beyond lipid-lowering, statins exert cardioprotective effects. High-dose statin treatment seems to reduce cardiovascular complications in high-risk patients. The ideal timing and administration regime remain unknown. OBJECTIVES: This study compared the cardioprotective effects of intravenous statin administration during myocardial infarction (MI) with oral administration immediately post-MI. METHODS: Hypercholesterolemic pigs underwent MI induction (90 min of ischemia) and were kept for 42 days. Animals were distributed in 3 arms (A): A1 received an intravenous bolus of atorvastatin during MI; A2 received an intravenous bolus of vehicle during MI; and A3 received oral atorvastatin within 2 h post-MI. A1 and A3 remained on daily oral atorvastatin for the following 42 days. Cardiac magnetic resonance analysis (days 3 and 42 post-MI) and molecular/histological studies were performed. RESULTS: At day 3, A1 showed a 10% reduction in infarct size compared with A3 and A2 and a 50% increase in myocardial salvage. At day 42, both A1 and A3 showed a significant decrease in scar size versus A2; however, A1 showed a further 24% reduction versus A3. Functional analyses revealed improved systolic performance in A1 compared with A2 and less wall motion abnormalities in the jeopardized myocardium versus both groups at day 42. A1 showed enhanced collagen content and AMP-activated protein kinase activation in the scar, increased vessel density in the penumbra, higher tumor necrosis factor α plasma levels and lower peripheral blood mononuclear cell activation versus both groups. CONCLUSIONS: Intravenous administration of atorvastatin during MI limits cardiac damage, improves cardiac function, and mitigates remodeling to a larger extent than when administered orally shortly after reperfusion. This therapeutic approach deserves to be investigated in ST-segment elevation MI patients.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Mendieta G, Ben-Aicha S, Gutiérrez M, et al. Intravenous Statin Administration During Myocardial Infarction Compared With Oral Post-Infarct Administration. J Am Coll Cardiol. 2020. PMID: 32216907. doi:10.1016/j.jacc.2020.01.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。